Skip to main content

LLY Stock Jumps After FDA Approves Eli Lilly’s Tirzepatide Drug For Weight Loss

Eli Lilly And Co’s ​stock saw a notable surge, trading at $610.50, up 1.69% (+$10.14) today, following the Food and Drug Administration’s approval of their blockbuster drug tirzepatide for weight loss.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.